Portal de Periódicos da CAPES

IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy

2024; Frontiers Media; Volume: 15; Linguagem: Inglês

10.3389/fimmu.2024.1331217

1664-3224

James G. Krueger, Kilian Eyerich, Vijay K. Kuchroo, Christopher T. Ritchlin, María T. Abreu, M. Merle Elloso, Anne M. Fourie, Steven Fakharzadeh, Jonathan P. Sherlock, Ya‐Wen Yang, J. Daniel, Iain B. McInnes,

Autoimmune and Inflammatory Disorders Research

Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis, psoriatic arthritis, and inflammatory bowel disease. We review IL-23 biology, IL-23 signaling in IMIDs, and the effect of IL-23 inhibition in treating these diseases. We propose studies to advance IL-23 biology and unravel differences in response to anti–IL-23 therapy. Experimental evidence generated from these investigations could establish a novel molecular ontology centered around IL-23–driven diseases, improve upon current approaches to treating IMIDs with IL-23 inhibition, and ultimately facilitate optimal identification of patients and, thereby, outcomes.